# Release Mechanism Selection

Select the drug release mechanism and delivery platform based on the therapeutic target, drug properties, and clinical requirements.

## Inputs

- `drug-properties`: Molecular weight, solubility, stability, therapeutic window, half-life, and required dosing duration
- `clinical-requirements`: Target tissue, route of administration, desired release profile (constant, pulsatile, triggered), and treatment duration

## Outputs

- `delivery-platform-selection`: Selected delivery system type with rationale (polymer matrix, reservoir, osmotic pump, microparticle, implant, transdermal)
- `target-release-profile`: Quantitative release rate vs time specification with therapeutic window bounds

## Process

1. Map drug properties to feasible delivery platforms. Low molecular weight, lipophilic drugs suit transdermal or matrix systems. Peptides and proteins need protection from degradation, pointing toward encapsulation or reservoir systems. Long-duration (months) favors implants; days to weeks favors microparticles or osmotic pumps.
2. Define the target release profile from pharmacokinetic requirements. Zero-order (constant rate) maintains steady-state plasma levels within the therapeutic window. First-order gives an initial burst then decline. Pulsatile mimics natural secretion patterns.
3. For polymer-based systems, select the polymer: PLGA for biodegradable depot lasting weeks to months (tune degradation by lactide:glycolide ratio and molecular weight). EVA or silicone for non-degradable implants requiring surgical removal. PEG-based hydrogels for tissue-compatible in-situ forming depots.
4. For each candidate platform, estimate the feasibility: can it contain the required drug mass, achieve the target rate, survive the sterilization method, and remain stable during shelf life? Eliminate infeasible options before committing to development.
5. Select the primary platform and define a backup. Document the selection rationale including the risk of each option. The backup matters because formulation development frequently encounters unexpected drug-polymer interactions.

---

Copyright 2024-present The Wayfinder Trust. All rights reserved.
